Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 751460, 4 pages
http://dx.doi.org/10.1155/2015/751460
Research Article

Developing a Noninvasive Procedure Using Labeled Monoclonal Antibody Anti-VEGF (Bevacizumab) for Detection of Endometriosis

1Laboratório de Pesquisa de Ciências Farmacêuticas, Unidade de Farmácia, Centro Universitário Estadual da Zona Oeste, Rio de Janeiro, RJ, Brazil
2Programa de Pós-Graduação em Saúde Pública e Meio Ambiente, Escola Nacional de Saúde Pública, Fundação Oswaldo Cruz, Rio de Janeiro, RJ, Brazil
3University Hospital Pedro Ernesto, Nuclear Medicine Service, Rio de Janeiro, RJ, Brazil
4Laboratory of Nanoradiopharmaceuticals, 21741706 Rio de Janeiro, RJ, Brazil

Received 26 September 2014; Revised 20 February 2015; Accepted 25 February 2015

Academic Editor: Sanjay K. Agarwal

Copyright © 2015 Daniel Escorsim Machado et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. O. Burney and L. C. Giudice, “Pathogenesis and pathophysiology of endometriosis,” Fertility and Sterility, vol. 98, no. 3, pp. 511–519, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. E. Bulun, “Endometriosis,” The New England Journal of Medicine, vol. 360, no. 3, pp. 268–279, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Sinaii, K. Plumb, L. Cotton et al., “Differences in characteristics among 1,000 women with endometriosis based on extent of disease,” Fertility and Sterility, vol. 89, no. 3, pp. 538–545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Varma, T. Rollason, J. K. Gupta, and E. R. Maher, “Endometriosis and the neoplastic process,” Reproduction, vol. 127, no. 3, pp. 293–304, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. A. Sampson, “Peritoneal endometriosis due to menstrual dissemination of endometrial tissue into the peritoneal cavity,” American Journal of Obstetrics & Gynecology, vol. 14, pp. 422–469, 1927. View at Google Scholar
  6. R. N. Taylor, D. I. Lebovic, and M. D. Mueller, “Angiogenic factors in endometriosis,” Annals of the New York Academy of Sciences, vol. 955, pp. 89–100, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Folkman, “Angiogenesis: an organizing principle for drug discovery?” Nature Reviews Drug Discovery, vol. 6, no. 4, pp. 273–286, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. R. N. Taylor, J. Yu, P. B. Torres et al., “Mechanistic and therapeutic implications of angiogenesis in endometriosis,” Reproductive Sciences, vol. 16, no. 2, pp. 140–146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. D. E. Machado, M. S. Abrao, P. T. Berardo, C. M. Takiya, and L. E. Nasciutti, “Vascular density and distribution of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) are significantly higher in patients with deeply infiltrating endometriosis affecting the rectum,” Fertility and Sterility, vol. 90, no. 1, pp. 148–155, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. E. MacHado, P. T. Berardo, C. Y. Palmero, and L. E. Nasciutti, “Higher expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 (Flk-1) and metalloproteinase-9 (MMP-9) in a rat model of peritoneal endometriosis is similar to cancer diseases,” Journal of Experimental and Clinical Cancer Research, vol. 29, no. 1, article 4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. D. E. Machado, A. Palumbo-Júnior, J. M. Santos et al., “A GFP endometriosis model reveals important morphological characteristics of the angiogenic process that govern benign and malignant diseases,” Histology and Histopathology, vol. 29, pp. 903–912, 2014. View at Google Scholar
  12. S. Kennedy, A. Bergqvist, C. Chapron et al., “ESHRE guideline for the diagnosis and treatment of endometriosis,” Human Reproduction, vol. 20, no. 10, pp. 2698–2704, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. J. R. Q. Guimarães, Manual de Oncologia, BBS Editora, São Paulo, Brazil, 3rd edition, 2008.
  14. S. R. Berry, D. Cunningham, M. Michael et al., “Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and fluoropyrimidines for mCRC: first BEAT trial,” European Journal of Cancer Supplements, vol. 5, no. 4, abstract 3020, p. 241, 2007. View at Publisher · View at Google Scholar
  15. C. D. Blanke, C. Rankin, G. D. Demetri et al., “Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033,” Journal of Clinical Oncology, vol. 26, no. 4, pp. 626–632, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. Bukowski, F. Kabbinavar, R. A. Figlin et al., “Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC),” Journal of Clinical Oncology, vol. 24, no. 18, supplement 20, p. 4523, 2006. View at Google Scholar
  17. P. Carter, “Improving the efficacy of antibody-based cancer therapies,” Nature Reviews Cancer, vol. 1, no. 2, pp. 118–129, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. D. E. Machado, P. T. Berardo, R. G. Landgraf et al., “A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis with an antiangiogenic effect in a rat model,” Fertility and Sterility, vol. 93, no. 8, pp. 2674–2679, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. L. T. M. Sa, M. D. S. Albernaz, B. F. D. C. Patricio et al., “Biodistribution of nanoparticles: initial considerations,” Journal of Pharmaceutical and Biomedical Analysis, vol. 70, pp. 602–604, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. M. S. Albernaz, C. A. Ospina, A. M. Rossi, and R. Santos-Oliveira, “Radiolabelled nanohydroxyapatite with 99mTc: perspectives to nanoradiopharmaceuticals construction,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 42, no. 2, pp. 88–91, 2014. View at Publisher · View at Google Scholar
  21. S. R. Pinto, M. A. Sarcinelle, M. de Souza Albernaz et al., “In vivo studies: comparing the administration via and the impact on the biodistribution of radiopharmaceuticals,” Nuclear Medicine and Biology, vol. 41, no. 9, pp. 772–774, 2014. View at Publisher · View at Google Scholar
  22. R. O. Burney, “Biomarker development in endometriosis,” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 74, pp. 75–81, 2014. View at Publisher · View at Google Scholar